XM does not provide services to residents of the United States of America.
G
G

GSK

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Latest Zantac trial against Boehringer Ingelheim ends with hung jury

UPDATE 1-Latest Zantac trial against Boehringer Ingelheim ends with hung jury Adds detail from verdict in paragraph 2, case and counsel information By Brendan Pierson Nov 22 (Reuters) - A trial ended with a hung jury on Thursday in a California man's lawsuit alleging Boehringer Ingelheim's discontinued heartburn drug Zantac gave him bladder cancer.
G
P
S

Latest Zantac trial against Boehringer Ingelheim ends with hung jury

Latest Zantac trial against Boehringer Ingelheim ends with hung jury By Brendan Pierson Nov 22 (Reuters) - A trial ended with a hung jury on Thursday in a California man's lawsuit alleging Boehringer Ingelheim's discontinued heartburn drug Zantac gave him bladder cancer. The jury in California state court was evenly divided on whether to hold Boehringer Ingelheim liable, according to lawyers for plaintiff John Russell.
G
P
S

UK Stocks-Factors to watch on Nov 22

UPDATE 1-UK Stocks-Factors to watch on Nov 22 Adds new items, updates futures Nov 22 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Friday, with futures FFIc1 up 0.6%. * GSK: GSK GSK.L said that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
B
E
G

GSK's RSV vaccine gets Japan approval for adults aged 50 to 59

UPDATE 1-GSK's RSV vaccine gets Japan approval for adults aged 50 to 59 Adds context in paragraphs 2-5 Nov 22 (Reuters) - GSK GSK.L said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease. GSK's RSV vaccine Arexvy has been approved in Japan for adults aged 60 and over since September last year for the prevention of the disease caused by RSV, a common contagi
G

GSK says RSV vaccine gets nod in Japan for use in adults aged 50 to 59

GSK says RSV vaccine gets nod in Japan for use in adults aged 50 to 59 Nov 22 (Reuters) - GSK GSK.L said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease. Reporting by Aby Jose Koilparambil in Bengaluru; Edit
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.